Replies to post #249911 on Biotech Values

[DewDiligence]

Carmot recently filed to go public, so you can learn about the company from its Form S-1:

https://www.sec.gov/Archives/edgar/data/1490109/000119312523279847/d515311ds1.htm

Roche’s buyout trumped the planned IPO.

[jbog]

It's not amazing in my view, Look at the value of the market they're attempting to enter. I'm not we've ever seen an opportunity, besides Covid, that has ever been presented.

I have to guess that after Novo entered the Chinese market at a cost of $51 per month that Novo's cost per script is probably less than $15 per script. I'm very excited about Altimmune mostly because it's carrying a sub $300 million market cap. Alt is preparing a ph 3 trial (FDA Standard 5k patient) but they'll enter it with a partner or being acquired.

[DewDiligence]

Roche’s CT-388 GLP-1/GIP—>18.8% placebo-adjusted weight_loss_at_24wks—good_tolerability:

https://www.globenewswire.com/news-release/2024/05/16/2883079/0/en/Ad-hoc-announcement-pursuant-to-Art-53-LR-Roche-reports-positive-Phase-I-results-for-its-dual-GLP-1-GIP-receptor-agonist-CT-388-in-people-with-obesity.html

CT-388 is a once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist being developed for the treatment of obesity and type 2 diabetes (T2D). CT-388 was designed to have potent activity on both the GLP-1 and GIP receptors but with minimal to no ß-arrestin recruitment on either receptor. This biased signalling significantly minimises receptor internalisation and consequent desensitisation, which is expected to lead to prolonged pharmacological activity.

Dosing in the trial in question was weekly by subcutaneous injection.